news
Key hallmark of ALS is successfully reversed in laboratory
Scientists demonstrated how to reverse the incorrect localisation of three RNA-binding proteins in ALS, potentially leading to treatments.
List view / Grid view
Amyotrophic Lateral Sclerosis (ALS)
news
Prize winner uncovers how microbiome can combat neurodegeneration
Eran Blacher has won the NOSTER & Science Microbiome Prize for discovering the link between the microbiome and neurodegenerative diseases.
article
How engineered RNA binding proteins delivered in vivo by gene therapy could treat myotonic dystrophy
In this article, Dr Jim Burns discusses promising pre-clinical results of how a new platform could treat the root cause of many devastating genetic diseases including myotonic dystrophy type 1.
news
Synthetic antibody treats congenital myasthenia in mice
Researchers have designed an antibody that attaches to MuSK, which prevented early lethality of mice with congenital myasthenia.
article
Developing bioenergetic nanocatalysts, a novel approach to treat neurodegeneration
Mark Mortenson, CSO of Clene Nanomedicine, discusses the use of proprietary gold nanocrystals as catalysts to prevent the progression of, and act as a treatment for, neurodegenerative disease.
news
Structure of protein that triggers neurodegeneration isolated and analysed
Using X-ray crystallography and cryo-electron microscopy, researchers have elucidated the structure of the SARM1 protein, a target for neurodegeneration.
news
Neuron damage from ALS reversed with new compound
Scientists have developed a compound that stops the degeneration of upper motor neurons, a contributor to amyotrophic lateral sclerosis (ALS).
news
Disrupted RNA transportation results in neurodegeneration
Researchers report that reduced TDP-43 expression disrupts axonal transport of messenger RNAs to cause neurodegeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).
news
Researchers develop promising new drug candidates to treat ALS
Scientists have shown that a Selenium-based drug-molecule called ebselen and other novel compounds can delay ALS onset in mouse models.
news
Researchers identify promising drug target for Huntington’s disease
Researchers have found the TBK1 enzyme regulates the degradation and clearance of the huntingtin protein, making it a drug target for Huntington's disease.
news
Study reveals potential targets for upper motor neuron disease therapies
The researchers revealed the mechanism by which signalling becomes dysfunctional in upper motor neuron (UMN) diseases, such as amyotrophic lateral sclerosis (ALS).
article
Refreshing how we approach neuroscience with a novel screening technology
Drug Target Review discusses how NETSseq, a novel profiling technology, is bringing new insights to neurodegenerative and psychiatric diseases.
news
L-serine could be used to treat ALS, after promising results in primate study
Researchers have shown that, when treated with L-serine, a non-human primate model of ALS had fewer pathologies associated with the disease.
news
Gene found to protect motor neurons against degeneration
Results of an international collaboration show promise for the future of motor neurone disease treatment efforts, as protective gene is identified.
news
Astrocytes could be harnessed to protect motor neurons in MND
Scientists using a new motor neuron disease (MND) model have shown astrocytes may protect neurons from toxic TDP-43 protein aggregates in the early stages of disease.